temanogrel + aspirin + clopidogrel

This drug is a **combination therapy** comprising temanogrel, aspirin, and clopidogrel. Temanogrel is a selective, peripherally acting inverse agonist of the 5-HT2A receptor, designed to inhibit serotonin-mediated vasoconstriction and platelet aggregation, investigated primarily for prevention/treatment of microvascular obstruction (MVO) during percutaneous coronary intervention (PCI)[2][4][8]. Aspirin and clopidogrel are both small molecule antiplatelet agents; aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), blocking thromboxane A2 and reducing platelet activation, whereas clopidogrel blocks the P2Y12 adenosine diphosphate receptor on platelet surfaces, preventing ADP-mediated platelet aggregation[1][3][5][7]. Together, this triple combination would act through synergistic antiplatelet and vasodilatory mechanisms, aiming to lower vascular thrombotic events and improve reperfusion outcomes post-PCI. Temanogrel has been developed by Arena Pharmaceuticals[2][4], and the combination approach is considered for patients at high risk of thrombosis and microvascular obstruction, such as those with acute coronary syndromes or during interventional cardiac procedures.

Other names

temanogrel + aspirin + clopidogrel